Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.

Mathew Thomas, Vinay; Gilreath, Jeffrey A; Newton, Shawn; Smock, Kristi J; Lim, Ming Y

Mathew Thomas, Vinay; Gilreath, Jeffrey A; Newton, Shawn; Smock, Kristi J; Lim, Ming Y.

Afiliação

Mathew Thomas V; Department of Internal Medicine, University of Connecticut, Farmington, CT, USA.
Gilreath JA; Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA.
Newton S; Department of Pharmacy Services, University of Utah Huntsman Cancer Hospital, Salt Lake City, UT, USA.
Smock KJ; Department of Pharmacy Services, University of Utah Huntsman Cancer Hospital, Salt Lake City, UT, USA.
Lim MY; Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA.

Haemophilia ; 27(4): e563-e566, 2021 Jul.

Article em En | MEDLINE | ID: mdl-33909921

Assuntos

Gamopatia Monoclonal de Significância Indeterminada; Paraproteinemias; Doenças de von Willebrand; Anticorpos Monoclonais/uso terapêutico; Humanos; Doenças de von Willebrand/complicações; Doenças de von Willebrand/tratamento farmacológico; Fator de von Willebrand

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / Doenças de von Willebrand / Gamopatia Monoclonal de Significância Indeterminada Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Haemophilia Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google